[{"data":1,"prerenderedAt":93},["ShallowReactive",2],{"media-slots-en":3,"wiki-item-en-cll-sll":61},{"about.hero":4,"about.video":6,"about.video-cover":8,"charity.hero":10,"contact.hero":12,"evidence.hero":14,"footer.qr-blood":16,"footer.qr-mini":18,"footer.qr-official":20,"footer.qr-solid":22,"guide.hero":24,"home.hero":26,"home.news-featured":28,"home.story-featured":30,"news.hero":32,"news.lead":34,"news.thumb":36,"stories.cover":41,"stories.hero":48,"stories.lead":50,"wiki.cat":52,"wiki.detail-hero":57,"wiki.hero":59},[5],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%B3%E4%BA%8E%E5%8D%9A%E5%8C%BB%E5%90%8C%E8%A1%8C_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[7],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_compressed.mp4",[9],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_frame1.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[11],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%AC%E7%9B%8A%E8%B5%84%E6%BA%90%E9%93%BE%E6%8E%A5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[13],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F08\u002Fbde8f2354d29ffca7dcfe395ef4711b2.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[15],"https:\u002F\u002Fwww.yyhmedical.com\u002Fimages\u002Fevidence\u002Fhero.jpg",[17],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-blood.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[19],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-mini.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[21],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-official.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[23],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-solid.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[25],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E7%96%BE%E7%97%85%E7%9F%A5%E8%AF%86%E5%BA%93_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[27],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E9%A6%96%E9%A1%B5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[29],"\u002Fimages\u002Fhome\u002Fnews-featured.jpg",[31],"\u002Fimages\u002Fhome\u002Fstory-featured.jpg",[33],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E5%8F%8B%E5%85%B3%E6%B3%A8_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[35],"\u002Fimages\u002Fnews\u002Flead.jpg",[37,38,39,40],"\u002Fimages\u002Fnews\u002Fn1.jpg","\u002Fimages\u002Fnews\u002Fn2.jpg","\u002Fimages\u002Fnews\u002Fn3.jpg","\u002Fimages\u002Fnews\u002Fn4.jpg",[42,43,44,45,46,47],"\u002Fimages\u002Fstories\u002Fs1.jpg","\u002Fimages\u002Fstories\u002Fs2.jpg","\u002Fimages\u002Fstories\u002Fs3.jpg","\u002Fimages\u002Fstories\u002Fs4.jpg","\u002Fimages\u002Fstories\u002Fs5.jpg","\u002Fimages\u002Fstories\u002Fs6.jpg",[49],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E8%80%85%E6%95%85%E4%BA%8B_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[51],"\u002Fimages\u002Fstories\u002Flead.jpg",[53,54,55,56],"\u002Fimages\u002Fwiki\u002Fcat-1.jpg","\u002Fimages\u002Fwiki\u002Fcat-2.jpg","\u002Fimages\u002Fwiki\u002Fcat-3.jpg","\u002Fimages\u002Fwiki\u002Fcat-4.jpg",[58],"\u002Fimages\u002Fwiki\u002Fdetail-hero.jpg",[60],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%8A%97%E7%99%8C%E7%99%BE%E7%A7%91_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",{"slug":62,"category":63,"categoryName":64,"title":65,"summary":66,"toc":67,"ymyl":90,"hasAlternate":92,"updatedAt":73},"cll-sll","blood","Hematologic Diseases","Chronic Lymphocytic Leukemia \u002F Small Lymphocytic Lymphoma (CLL\u002FSLL)","Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different clinical forms of the same mature B-cell cancer. They usually grow slowly and are most common in older adults.",[68,74,78,82,86],{"key":69,"title":70,"html":71,"icon":72,"updatedAt":73},"","Overview","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have essentially the same cellular, immunophenotypic, and biological features and are considered \u003Cstrong>different clinical forms of the same disease\u003C\u002Fstrong>.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">The distinction is based mainly on where the abnormal B cells are found:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">CLL:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> Abnormal B cells are found primarily in the blood and bone marrow and may also involve the lymph nodes, spleen, and other tissues.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">SLL:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> Abnormal B cells are found mainly in the lymph nodes or other lymphoid tissues, with relatively few abnormal cells in the blood.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 7px 0 7px 72px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">CLL\u002FSLL usually progresses slowly. Many people have no symptoms when they are diagnosed, and the disease may be discovered during a routine blood test or physical exam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A diagnosis of CLL\u002FSLL does not always mean that treatment needs to start right away.\u003C\u002Fstrong> People without indications for treatment are often monitored regularly.\u003C\u002Fspan>\u003C\u002Fp>","⚕️","2026-10-09",{"key":69,"title":75,"html":76,"icon":77,"updatedAt":73},"Causes and Risk Factors","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">The exact cause of CLL\u002FSLL is not known. The disease develops through a series of genetic and molecular changes in B lymphocytes that allow abnormal cells to survive longer than they normally would and gradually build up in the blood, bone marrow, lymph nodes, and other tissues.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Factors that may be associated with an increased risk include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">Age:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> CLL\u002FSLL is most common in older adults.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">Family history:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> Having a close relative with CLL\u002FSLL or certain other blood cancers may increase the risk.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">Sex:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> CLL is more common in men than in women.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">Certain environmental or occupational exposures:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> Some exposures may be associated with an increased risk, although their role is still being studied.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Having one or more risk factors does not mean that someone will develop CLL\u002FSLL, and many people diagnosed with the disease have no known risk factors.\u003C\u002Fspan>\u003C\u002Fp>","🧬",{"key":69,"title":79,"html":80,"icon":81,"updatedAt":73},"Signs and Symptom","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Many people with CLL\u002FSLL have no symptoms in the early stages. \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">When symptoms do occur, they may include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Painless swelling of lymph nodes in the neck, armpits, or groin\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Ongoing fatigue or weakness\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Unexplained fever\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Drenching night sweats\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Unexplained weight loss\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Frequent or persistent infections\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Easy bruising or bleeding\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Abdominal fullness or discomfort caused by an enlarged spleen\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Feeling full after eating only a small amount\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Shortness of breath\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Some patients may also develop anemia, a low platelet count, or other blood cell abnormalities if normal blood cell production is affected.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">These symptoms can also be caused by other conditions. Testing is needed to determine whether they are related to CLL\u002FSLL.\u003C\u002Fspan>\u003C\u002Fp>","📋",{"key":69,"title":83,"html":84,"icon":85,"updatedAt":73},"Diagnosis","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Diagnosis of CLL\u002FSLL may involve blood tests, flow cytometry, tissue pathology, and genetic and molecular testing. Because CLL and SLL differ mainly in where the abnormal B cells are found, the diagnostic approach may differ between the two.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Blood Tests\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">A complete blood count (CBC) measures white blood cells, lymphocytes, red blood cells, and platelets.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">When CLL is suspected, the healthcare team evaluates the number and persistence of abnormal B cells in the blood and looks for abnormalities such as anemia or a low platelet count.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Flow Cytometry and Immunophenotyping\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Flow cytometry examines specific markers on the surface of abnormal B cells and is an important test for diagnosing CLL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">CLL\u002FSLL has a characteristic immunophenotype. These findings can help confirm the diagnosis and distinguish CLL\u002FSLL from other B-cell lymphomas.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Tissue Biopsy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">For patients suspected of having SLL—particularly those with enlarged lymph nodes but without enough abnormal B cells in the blood to meet the criteria for CLL—a biopsy of an affected lymph node or other tissue is usually needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Pathology and immunohistochemistry can help confirm SLL and distinguish it from other types of lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Genetic and Molecular Testing\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Genetic and molecular testing plays an important role in assessing CLL\u002FSLL and selecting treatment.\u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">Common tests include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">FISH:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> Can identify chromosomal abnormalities such as del(17p), del(11q), trisomy 12, and del(13q).\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">TP53 testing:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> TP53 abnormalities are important for assessing disease risk and selecting treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">IGHV mutation status:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> Provides important information about the biology and prognosis of the disease.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">In particular, findings such as \u003Cstrong>TP53 abnormalities and del(17p)\u003C\u002Fstrong> can directly influence treatment decisions, so these results are often evaluated when treatment is being considered.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Bone Marrow Tests\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Bone marrow testing is not required for every patient when CLL\u002FSLL is diagnosed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">A bone marrow aspiration and\u002For biopsy may be performed in selected cases to evaluate bone marrow involvement, investigate the cause of low blood cell counts, or provide additional information needed for treatment.\u003C\u002Fspan>\u003C\u002Fp>","🩺",{"key":69,"title":87,"html":88,"icon":89,"updatedAt":73},"Treatment","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Treatment for CLL\u002FSLL depends on \u003Cstrong>whether there are indications for treatment, the characteristics of the disease, genetic and molecular test results, age, overall health, and previous treatments\u003C\u002Fstrong>.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Not everyone with CLL\u002FSLL needs treatment right away.\u003C\u002Fstrong> For people without indications for treatment, starting therapy early generally does not provide a clear benefit, so regular monitoring may be recommended.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">With the development of targeted therapies, treatment for CLL\u002FSLL has changed significantly, and many patients can now receive targeted therapy–based treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Active Surveillance (Watch and Wait)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">For people without symptoms or other indications for treatment, regular monitoring may be recommended instead of starting treatment immediately.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Follow-up usually includes a review of symptoms, physical exams, and blood tests. The healthcare team monitors changes in lymphocyte counts, lymph nodes and spleen size, other blood cell counts, and the development of new symptoms.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">If the disease remains stable, monitoring can continue. Treatment can be started if the disease progresses or other indications for treatment develop.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Targeted Therapy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Targeted therapy is now one of the most important approaches to treating CLL\u002FSLL. \u003C\u002Fstrong>\u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">Major types of targeted therapy include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">BTK inhibitors:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> These drugs interfere with signaling pathways that CLL\u002FSLL cells use to grow and survive.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"margin: 7px 0;\">\u003Cstrong style=\"font-size: 15px;\">BCL-2 inhibitors:\u003C\u002Fstrong>\u003Cspan style=\"font-size: 15px;\"> These drugs block the BCL-2 protein and help trigger the death of lymphoma cells.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 7px 0;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">These medications may be used alone or combined with treatments such as anti-CD20 monoclonal antibodies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">The choice of treatment depends on factors such as TP53\u002Fdel(17p) and IGHV status, overall health, other medical conditions, and previous treatments.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Anti-CD20 Monoclonal Antibodies\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">CLL\u002FSLL cells typically express CD20. Anti-CD20 monoclonal antibodies, such as \u003Cstrong>obinutuzumab or rituximab\u003C\u002Fstrong>, can help the immune system recognize and attack abnormal B cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">These medications are often combined with other treatments depending on the individual situation.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Chemotherapy and Chemoimmunotherapy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Chemotherapy and chemoimmunotherapy were widely used for CLL\u002FSLL in the past.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">With the development of BTK inhibitors, BCL-2 inhibitors, and other targeted therapies, \u003Cstrong>traditional chemotherapy is no longer the main first-line approach for many patients\u003C\u002Fstrong>.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Chemotherapy or chemoimmunotherapy may still be considered in selected situations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Relapsed or Refractory CLL\u002FSLL\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Some patients may experience disease progression after treatment or may not respond adequately to previous therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Treatment for relapsed or refractory CLL\u002FSLL depends on previous medications, duration of response, resistance patterns, biological features such as TP53 status, and overall health.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">New targeted therapies, immunotherapies, and cellular therapies continue to expand treatment options for relapsed or refractory disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>CAR T-Cell Therapy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">For selected patients with CLL\u002FSLL that remains relapsed or refractory after multiple treatments, \u003Cstrong>CAR T-cell therapy\u003C\u002Fstrong> may be an option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">CAR T-cell therapy involves collecting a patient’s own T cells and modifying them in a laboratory so they can recognize a specific target on cancer cells. The modified cells are then expanded and infused back into the patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Whether CAR T-cell therapy is appropriate depends on previous treatments, disease status, age, overall health, and treatment eligibility.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Hematopoietic Stem Cell Transplantation (HSCT)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">With the development of targeted therapies and other newer treatments, \u003Cstrong>allogeneic hematopoietic stem cell transplantation (allo-HSCT) is no longer a routine treatment for most people with CLL\u002FSLL\u003C\u002Fstrong>.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">For a small number of patients with high-risk disease that remains difficult to control after multiple treatments, allogeneic HSCT may be considered.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">The decision depends on disease risk, response to previous treatments, age, overall health, and donor availability.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 7px;margin-bottom: 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Clinical Trials\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin: 7px 0;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Treatment for CLL\u002FSLL continues to evolve. Clinical trials are studying new targeted therapies, immunotherapies, cellular therapies, and treatment combinations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Clinical trials may be available for both newly diagnosed and relapsed or refractory CLL\u002FSLL.\u003C\u002Fspan>\u003C\u002Fp>","💊",{"author":69,"reviewedBy":69,"lastReviewed":69,"datePublished":69,"citations":91,"disclaimer":69},[],false,1792294327863]